Bolt Biotherapeutics (BOLT)vsVertex Pharmaceuticals Inc (VRTX)
BOLT
Bolt Biotherapeutics
$5.80
-4.61%
HEALTHCARE · Cap: $14.33M
VRTX
Vertex Pharmaceuticals Inc
$537.79
-0.15%
HEALTHCARE · Cap: $137.57B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 275466% more annual revenue ($12.95B vs $4.70M). VRTX leads profitability with a 30.7% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 58/100 (C).
BOLT
Avoid29
out of 100
Grade: F
VRTX
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BOLT.
Margin of Safety
+44.9%
Fair Value
$977.14
Current Price
$537.79
$439.35 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 37.8%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 39.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : BOLT
The strongest argument for BOLT centers on Price/Book.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 30.7% and operating margin at 37.8%. Revenue growth of 11.8% demonstrates continued momentum.
Bear Case : BOLT
The primary concerns for BOLT are EPS Growth, Market Cap, Profit Margin. Debt-to-equity of 1.71 is elevated, increasing financial risk.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
BOLT profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
BOLT carries more volatility with a beta of 1.01 — expect wider price swings.
VRTX is growing revenue faster at 11.8% — sustainability is the question.
VRTX generates stronger free cash flow (546M), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (58/100 vs 29/100), backed by strong 30.7% margins and 11.8% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Bolt Biotherapeutics
HEALTHCARE · BIOTECHNOLOGY · USA
Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the discovery, development and commercialization of pharmaceutical products. The company is headquartered in Redwood city, California.
Visit Website →Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?